Inspire Medical Systems Inc
F:2DR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Inspire Medical Systems Inc
F:2DR
|
US |
|
M
|
Mattel Inc
XMUN:MTT
|
US |
|
C
|
CVS Health Corp
XBER:CVS
|
US |
|
I
|
Ionis Pharmaceuticals Inc
XMUN:ISI
|
US |
|
Adicet Bio Inc
F:1IJ
|
US |
|
Canon Electronics Inc
TSE:7739
|
JP |
|
S
|
Scor SE
OTC:SZCRF
|
FR |
|
I
|
ITV PLC
XMUN:IJ7
|
UK |
|
F
|
Fresh Del Monte Produce Inc
SWB:FDM
|
US |
Inspire Medical Systems Inc
Inspire Medical Systems makes an implantable device that treats obstructive sleep apnea, a condition where the airway repeatedly closes during sleep. Its system works like a small pacemaker for breathing: a surgeon implants it under the skin, and it sends mild stimulation to a nerve that helps keep the airway open at night. The company’s main product is this therapy system, along with the tools and support needed to implant and use it. Its customers are mostly hospitals, sleep surgeons, and ear, nose, and throat specialists who select and implant the device for patients who have not done well with standard sleep apnea treatments such as CPAP. Inspire makes money by selling the device system and related components through the medical device supply chain, usually tied to the implantation procedure. In practice, the company sits between the doctor who diagnoses sleep apnea and the hospital or surgery center that performs the implant. What makes the business different is that it is not a broad sleep-apnea supplier or a disposable-device maker. It is focused on one specific treatment option for one specific patient group: people with moderate to severe obstructive sleep apnea who need an implanted alternative to masks and machines. That narrow focus gives it a clear role in sleep medicine and makes its business depend on physician adoption, patient selection, and reimbursement for an implanted therapy.
Inspire Medical Systems makes an implantable device that treats obstructive sleep apnea, a condition where the airway repeatedly closes during sleep. Its system works like a small pacemaker for breathing: a surgeon implants it under the skin, and it sends mild stimulation to a nerve that helps keep the airway open at night. The company’s main product is this therapy system, along with the tools and support needed to implant and use it.
Its customers are mostly hospitals, sleep surgeons, and ear, nose, and throat specialists who select and implant the device for patients who have not done well with standard sleep apnea treatments such as CPAP. Inspire makes money by selling the device system and related components through the medical device supply chain, usually tied to the implantation procedure. In practice, the company sits between the doctor who diagnoses sleep apnea and the hospital or surgery center that performs the implant.
What makes the business different is that it is not a broad sleep-apnea supplier or a disposable-device maker. It is focused on one specific treatment option for one specific patient group: people with moderate to severe obstructive sleep apnea who need an implanted alternative to masks and machines. That narrow focus gives it a clear role in sleep medicine and makes its business depend on physician adoption, patient selection, and reimbursement for an implanted therapy.
Revenue: First-quarter revenue rose 1.6% to $204.6 million, but management said coding, reimbursement uncertainty, and the WISeR program reduced revenue by about $20 million.
Guidance cut: The company lowered full-year 2026 revenue guidance to $825 million to $875 million and now expects a $120 million to $150 million total hit from reimbursement-related issues and WISeR.
Q2 pressure: Management expects the hardest near-term impact in the second quarter, with revenue expected to be down 9% to 11% year over year and an adjusted operating loss of $10 million to $15 million.
Coding progress: Medicare saw progress with a new C-code for Inspire V procedures, but commercial payer coding remains messy and is slowing prior authorizations and patient flow.
Growth reset: Management still believes the disruption is temporary, expects sequential improvement in the second half of 2026, and reiterated a return to growth in 2027.
Cash strength: The balance sheet stayed strong with no debt and $400 million in cash and investments, while operating cash flow improved to $12.8 million.
